December 6
• As Senior Product Growth Manager at Oviva, you will be part of the DTx (Digital Therapeutics) Pathway Team, which sits within the wider Product Function. • You will report to the Head of DTx Pathways, while working closely with our CRM, Copy Writing and Product teams. • In this role, you will be responsible for improving the treatment journey as well as patient communication and experience for our DTx product with the ultimate goal to increase our patient lifetime value (LTV). • In this position, you will combine analytical and strategic aspects of product growth management with a comprehensive understanding of digital health.
• Product Growth Experience: You have at least 5 years of experience leading and executing product growth strategies, using influence rather than direct authority, in a cross-functional, high-growth environment. • Data-driven approach: You have the ability to create and implement measurement and tracking frameworks, conduct A/B testing, and use data-driven insights to develop strategies. • Digital health experience: You have experience in the area of digital health/therapeutics or healthcare technologies. • Stakeholder Management: You have extensive experience working with various and diverse stakeholders such as product, clinical leadership and clinical delivery. • Language skills: You speak German and English fluently (we work mainly in English, but the position is focused on German-speaking digital therapeutics).
• Pioneering Impact: Become part of a dedicated team that is revolutionizing healthcare for people with obesity and type 2 diabetes. • Dynamic Culture: Join an environment where creativity and collaboration drive meaningful change. • Competitive Benefits: Enjoy attractive salaries and a flexible work environment that supports your growth and well-being.
Apply NowDecember 1
Drive user acquisition strategy at SOFTGAMES, a leader in mobile gaming. Lead and grow a dynamic team remotely.
July 25
Manage account performance and lead strategic initiatives for B2B SaaS in DACH.